Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

The Omicron SARS-CoV-2 has several distinct sublineages, among which sublineage BA.1 is responsible for the initial Omicron surge and is now being replaced by BA.2 worldwide, whereas BA.3 is currently at a low frequency. The ongoing BA.1-to-BA.2 replacement underscores the importance to understand t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jing, Kurhade, Chaitanya, Xia, Hongjie, Liu, Mingru, Xie, Xuping, Ren, Ping, Shi, Pei-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135681/
https://www.ncbi.nlm.nih.gov/pubmed/35618703
http://dx.doi.org/10.1038/s41467-022-30580-5
_version_ 1784714015535005696
author Zou, Jing
Kurhade, Chaitanya
Xia, Hongjie
Liu, Mingru
Xie, Xuping
Ren, Ping
Shi, Pei-Yong
author_facet Zou, Jing
Kurhade, Chaitanya
Xia, Hongjie
Liu, Mingru
Xie, Xuping
Ren, Ping
Shi, Pei-Yong
author_sort Zou, Jing
collection PubMed
description The Omicron SARS-CoV-2 has several distinct sublineages, among which sublineage BA.1 is responsible for the initial Omicron surge and is now being replaced by BA.2 worldwide, whereas BA.3 is currently at a low frequency. The ongoing BA.1-to-BA.2 replacement underscores the importance to understand the cross-neutralization among the three Omicron sublineages. Here we test the neutralization of BA.1-infected human sera against BA.2, BA.3, and USA/WA1-2020 (a strain isolated in late January 2020). The BA.1-infected sera neutralize BA.1, BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geometric mean titers (GMTs) of 445, 107, 102, and 16, respectively. Thus, the neutralizing GMTs against heterologous BA.2, BA.3, and USA/WA1-2020 are 4.2-, 4.4-, and 28.4-fold lower than the GMT against homologous BA.1, respectively. These findings have implications in COVID-19 vaccine strategy.
format Online
Article
Text
id pubmed-9135681
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91356812022-05-28 Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2 Zou, Jing Kurhade, Chaitanya Xia, Hongjie Liu, Mingru Xie, Xuping Ren, Ping Shi, Pei-Yong Nat Commun Article The Omicron SARS-CoV-2 has several distinct sublineages, among which sublineage BA.1 is responsible for the initial Omicron surge and is now being replaced by BA.2 worldwide, whereas BA.3 is currently at a low frequency. The ongoing BA.1-to-BA.2 replacement underscores the importance to understand the cross-neutralization among the three Omicron sublineages. Here we test the neutralization of BA.1-infected human sera against BA.2, BA.3, and USA/WA1-2020 (a strain isolated in late January 2020). The BA.1-infected sera neutralize BA.1, BA.2, BA.3, and USA/WA1-2020 SARS-CoV-2s with geometric mean titers (GMTs) of 445, 107, 102, and 16, respectively. Thus, the neutralizing GMTs against heterologous BA.2, BA.3, and USA/WA1-2020 are 4.2-, 4.4-, and 28.4-fold lower than the GMT against homologous BA.1, respectively. These findings have implications in COVID-19 vaccine strategy. Nature Publishing Group UK 2022-05-26 /pmc/articles/PMC9135681/ /pubmed/35618703 http://dx.doi.org/10.1038/s41467-022-30580-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zou, Jing
Kurhade, Chaitanya
Xia, Hongjie
Liu, Mingru
Xie, Xuping
Ren, Ping
Shi, Pei-Yong
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
title Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
title_full Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
title_fullStr Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
title_full_unstemmed Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
title_short Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
title_sort cross-neutralization of omicron ba.1 against ba.2 and ba.3 sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135681/
https://www.ncbi.nlm.nih.gov/pubmed/35618703
http://dx.doi.org/10.1038/s41467-022-30580-5
work_keys_str_mv AT zoujing crossneutralizationofomicronba1againstba2andba3sarscov2
AT kurhadechaitanya crossneutralizationofomicronba1againstba2andba3sarscov2
AT xiahongjie crossneutralizationofomicronba1againstba2andba3sarscov2
AT liumingru crossneutralizationofomicronba1againstba2andba3sarscov2
AT xiexuping crossneutralizationofomicronba1againstba2andba3sarscov2
AT renping crossneutralizationofomicronba1againstba2andba3sarscov2
AT shipeiyong crossneutralizationofomicronba1againstba2andba3sarscov2

Ejemplares similares